Summit Therapeutics Inc. (SMMT) Earnings Call Transcripts
Summit Therapeutics Inc.'s Latest Earnings Call - June 1, 2026
In the second quarter of fiscal year 2026, Summit Therapeutics Inc. (SMMT:US) showcased significant advancements in its oncology pipeline, particularly with the Phase III HARMONi-6 trial results for ivonescimab. The trial demonstrated a statistically significant overall survival (OS) benefit with a hazard ratio of 0.66, indicating a 4-month improvement in median survival compared to tislelizumab. Management expressed optimism about the implications of these results for ongoing studies, particularly HARMONi-3, and confirmed that they expect to report further data in the second half of 2026. Revenue figures and earnings details were not disclosed during the call, but management's confidence in ivonescimab's potential as a new standard of care could drive future stock performance.
Reported metrics
| Metric | Value |
|---|---|
| Overall Survival Hazard Ratio | 0.66 (beat) |
| Adjusted Response Rate in CRC | 70.8% (beat) |
| Disease Control Rate in CRC | 100% (beat) |
| Enrollment in HARMONi-3 | Completed (positive) |
| PDUFA Date for BLA Filing | November 14, 2026 (positive) |
| Median Follow-Up Time for HARMONi-6 | 21.4 months (neutral) |
Guidance from management
Management expects to report final PFS and interim OS results for the HARMONi-3 trial in the second half of 2026, maintaining confidence in the ongoing studies.
What management said
Thanks, Salveen. Why don't we start with the first question that you asked there with respect. Can you repeat the first question? I just want to make sure I've got full context on the first question.
And Salveen, this is Allen. I'd add to -- I understand the question about staying this translating over to non-squamous a greater unmet need in Western markets. I want to point out the HARMONi and HARMONi-A study. Those were nonsanctologies with the same chemo backbone, even though they are EGFR mutant non-mall cell lung cancer. And again, all the strong ivonescimab data in complete different tumor types of CRC TNBC....
What analysts pressed on
Analysts expressed concerns regarding the translation of HARMONi-6 results to the ongoing HARMONi-3 trial, particularly regarding the potential impact of baseline imbalances in older patients. There were also questions about the statistical significance of interim analyses and how they might affect future guidance.
Main topics on the call
- HARMONi-6 Trial Results — The HARMONi-6 trial for ivonescimab demonstrated a statistically significant overall survival benefit with a hazard ratio of 0.66 and a median survival improvement of at least 4 months over tislelizumab. Management state...
- Phase II Colorectal Cancer Data — Encouraging Phase II data for ivonescimab in metastatic colorectal cancer was presented, showing a 70.8% adjusted response rate and a 100% disease control rate when combined with FOLFOX chemotherapy. Management noted, 'T...
- Future Trials and Guidance — Management indicated that the final PFS and interim OS analysis for the HARMONi-3 trial are expected in the second half of 2026. They stated, 'We look forward to the results of the final PFS and interim OS in the second ...
- Market Potential — Summit highlighted the potential market opportunity for ivonescimab, estimating a total addressable market exceeding $100 billion globally. The company noted, 'Ivonescimab has the potential to become a new standard of ca...
Read the full Summit Therapeutics Inc. transcript (June 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 31 calls on record spanning June 24, 2020 to July 23, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 31 Summit Therapeutics Inc. earnings call transcripts on record, spanning June 24, 2020 to July 23, 2026. Based on this history, Summit Therapeutics Inc. reports quarterly. The most recent call on file is dated July 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- SMMT
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 31
- First call
- June 24, 2020
- Most recent
- July 23, 2026
- Reporting cadence
- quarterly